Search results
Results from the WOW.Com Content Network
In May 2015, the company announced its intention to acquire Stage Cell Therapeutics for up to $223 million. [6] Later in the same month the company launched a collaboration, with Editas Medicine, to create CAR-T and high-affinity T cell receptor therapies to treat cancer, with the potential to generate up to $737 million-plus for Editas. [7]
Axicabtagene ciloleucel (KTE-C19, ZUMA-3, YESCARTA) was an investigational therapy (for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)) in which a patient's T cells were genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. [11]
Due to the high costs of CAR T cell therapy, [116] a number of alternative efforts are being investigated to improve CAR T cell manufacturing and reduce costs. In vivo CAR T cell manufacturing strategies [117] [118] are being tested. In addition, bioinstructive materials have been developed for CAR T cell generation. [119]
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
It will also look at improving manufacturing of Chimeric antigen receptor T cell (CAR T cells). Finally, the deal "will also apply AI to generative chemistry to enhance drug design". [ 74 ] In November 2019, Sandoz announced it would acquire the Japanese business of Aspen Global inc for €300 million (around $330 million), boosting the ...
The search engine that helps you find exactly what you're looking for. Find the most relevant information, video, images, and answers from all across the Web.
CAR-T kill tumor cells specifically by targeting the tumor-associated antigens to keep the damage to healthy tissue at a minimum level. Additionally, these engineered T-cells can perform their function independent from HLA - major histocompatibility complex (MHC) presentation. Furthermore, CAR structure can be manipulated flexibly to target ...
Lineage is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. The company changed its name from BioTime Inc. to Lineage Cell Therapeutics less than one year following its appointment of a new CEO, Brian Culley, in August 2018 and completing a series of corporate transactions including the distribution of AgeX Therapeutics, the acquisition of ...